Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Gilead

The Testaments to Big Mistakes: the seven best shows to stream this week

Chase Infiniti stars in Margaret Atwood’s gripping sequel to the Handmaid’s Tale, plus Dan Levy’s irresistibly goofy new sitcom will thrill Schitt’s Creek fans

The Guardian - UK

‘No more than a drop in the ocean’: this drug could end new HIV infections in Eswatini – why isn’t there enough?

The southern Africa country has the world’s highest prevalence of HIV but the amount of lenacapavir reaching it is too small to reach all those at risk

The Guardian - UK

Gilead Sciences's Q1 2026 Earnings: What to Expect

Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

From 'The Boys' to 'Euphoria': 23 best new shows and movies streaming in April

Our guide to all the new shows and movies from all the best streaming services and TV networks in April 2026. Find out what to watch this month

Tom’s Guide

3 Top-Rated Stocks to Buy to Hedge Against Stagflation as Middle East Conflict Drags On

Amid widespread uncertainties, these three names can shield your portfolio.

Barchart

3 Blue-Chip Stocks Built for a Rotating Market

Investors are rotating out of overvalued mega-cap tech as the broader economy heats up; these three blue-chip stocks are attracting attention

MarketBeat

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Three companies with a combination of excellent name recognition within their industries and strong free cash flow potential provide a stable investment option.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

Barchart

This Overlooked Biotech Giant Could Surprise Investors This Quarter

Investors may be underestimating the long-term potential of Gilead’s evolving portfolio.

Barchart

Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?

Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

A sequel taking place years after The Handmaid’s Tale is coming to Disney+

The show takes place roughly five years after the events of The Handmaid’s Tale

The Independent UK

The 'Handmaid's Tale' Sequel Finally Has A Release Date

'The Testaments' is continuing Margaret Atwood's dystopian tale in 2026.

Inverse

3 Cash-Flow Machines Investors May Want Heading Into 2026

A company's cash flow can reveal its day-to-day success and sustainability, and these three firms are all thriving when it comes to cash generation.

MarketBeat

Five big global health wins in 2025 that will save millions of lives

From HIV to TB, scientists and doctors made breakthroughs in treatment and prevention of some of the world’s deadliest diseases

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains

GILD, AMAT, and QCOM all stand out for their capacity to generate cash flow, which allows them to increase value to shareholders through dividends and buybacks.

The Independent UK

HIV ‘vaccine’ will reach just 7% of people needed to end Aids pandemic

The figure comes as the UN reports a ‘devastating’ collapse of HIV prevention services around the world

Benzinga

The Insider Report: Prepare for the Next Dip Buying Opportunity

The turbulence in stocks continued with the Nasdaq reeling from the tech wreck. It finished down 2.74%, while the Dow Jones Industrial Average and the SP 500 finished down 1.91% and 1.94%, respectively. The rotation into healthcare continues to accelerate, and it's really the only sector offering abundant and attractive…

The Independent UK

Eswatini is the first African country to get twice-yearly HIV prevention shot

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global health officials call a game-changer

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Cash-Rich Stocks With High Growth Potential Right Now

Discover three high free cash flow yield stocks—Salesforce, Applied Materials, and Gilead Sciences—offering stability and long-term growth potential

Benzinga

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.

Barchart

Is Wall Street Bullish or Bearish on Gilead Sciences Stock?

Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.

The Independent UK

South Africa's health minister hails new HIV prevention jab but warns of limited supply

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool against the disease

Benzinga

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.

The Independent UK

Landmark deals for cheaper ‘pandemic-ending’ HIV jab hailed as ‘huge’ step forward

Linda-Gail Bekker, who helped prove the drug Lenacapavir’s effectiveness, tells The Independent that $40 doses bring hope – but aid cuts still risk its rollout

The Guardian - UK

Cheap supplies of HIV-prevention jab for poorer countries hailed as ‘genuine chance to end’ global epidemic

Lenacapavir described as ‘next best thing’ to an HIV vaccine will cost $40 a year for each patient in 120 countries from 2027, funders say

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.